Urine-derived long non-coding RNA prostate cancer antigen-3 (PCA3) is the first US FDA approved urinary biomarker for PCa to aid decision making for repeated biopsies 14, while its ability in detecting the aggressiveness of PCa is limited 15. The gene discussed is PCA3; the disease is posterior cortical atrophy.